ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of “Buy” by Analysts

ProQR Therapeutics (NASDAQ:PRQR) has been assigned an average rating of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $9.50.

Several equities analysts recently issued reports on the stock. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, March 14th. Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Monday, March 10th. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its holdings in ProQR Therapeutics by 164.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company’s stock valued at $25,446,000 after buying an additional 5,976,813 shares during the period. Woodline Partners LP purchased a new position in shares of ProQR Therapeutics in the 4th quarter valued at $9,426,000. Millennium Management LLC lifted its holdings in shares of ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company’s stock valued at $7,492,000 after acquiring an additional 2,683,351 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in ProQR Therapeutics during the 4th quarter worth $7,486,000. Finally, DAFNA Capital Management LLC increased its holdings in ProQR Therapeutics by 73.1% in the 4th quarter. DAFNA Capital Management LLC now owns 1,567,561 shares of the biopharmaceutical company’s stock valued at $4,154,000 after purchasing an additional 661,979 shares in the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Trading Up 2.3 %

Shares of PRQR stock opened at $1.35 on Wednesday. The company has a market capitalization of $142.04 million, a price-to-earnings ratio of -4.22 and a beta of 0.25. The firm has a 50-day moving average price of $1.70 and a 200 day moving average price of $2.51. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.62.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).